SCHEMBL7735517

SCHEMBL7735517

CCOC(=O)c1c(-c2cccc(OC)c2)cc[nH]c1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
KDM4E B2RXH2 6/20 0.54
HPGD P15428 4/20 0.47
HSD17B10 Q99714 4/20 0.47
TP53 P04637 1/20 0.47
LMNA P02545 2/20 0.47
PADI4 Q9UM07 1/20 0.47
MAPT P10636 4/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP3 P42574 1/20 0.46
RAB9A P51151 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PPARG P37231 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5885102 0.77 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL27294436 0.76 PRKCZ (0.54) ALDH1A1KDM4EHPGDTP53LMNA
SCHEMBL7710797 0.75 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL689790 0.74 ALDH1A1 (0.78) ALDH1A1HPGDHSD17B10LMNAMAPT
SCHEMBL3851864 0.74 KDM4E (0.53) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL7737830 0.73 GRM2 (0.49) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL16386608 0.72 ALDH1A1 (0.57) ALDH1A1KDM4EHPGDLMNAMAPT
SCHEMBL5943816 0.71 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTSMN1; SMN2NPC1
SCHEMBL6300606 0.71 KDM4E (0.56) ALDH1A1KDM4EHPGDHSD17B10LMNA
SCHEMBL4714286 0.71 MAPT (0.77) TP53LMNAMAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6452008-B2 3-UREA COMPOUND FROM THE 3-AMIDO COMPOUND WITHOUT AZIDATION PROCESS WHICH HAS RISK OF EXPLOSION; REACTION WITH HYPOCHLORITE, HYPOBROMITE OR LEAD TETRAACETATE AND THEN AN AMINE; ACAT INHIBITOR SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-17 US disclosed
US-20010051732-A1 Pyridone derivatives and process for preparing the same SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2001-12-13 US disclosed
US-6300500-B1 Preparation of pyridone derivatives using phthalimido containing starting material SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-10-09 US disclosed
EP-1086948-A1 PYRIDONE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2001-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051732-A1 Pyridone derivatives and process for preparing the same HK1, HPD, ALK ALDH1A1 716/4885KDM4E 139/4885HPGD 2394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.